FORT LEE, N.J.--(BUSINESS WIRE)--Neurologix, Inc. (OTCBB:NRGX) (the “Company”), a biotechnology company developing innovative gene therapies for the brain and central nervous system, announced today its financial results for the second quarter and six months ended June 30, 2009.
